Saturday, November 21, 2026 · Edition updated 6:00 AM ETSAT, NOV 21 · 6 AM ET editionNext edition in Next --:--:--

Aging exacerbates muscle loss induced by semaglutide treatment in female mice

Early results, not yet checked by other scientists · bioRxiv · Nov 13, 2026

What this means

Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide, have transformed the pharmacological treatment of obesity. While highly efficacious in promoting weight loss, these drugs also induce substantial reductions in lean mass, raising concerns for skeletal muscle loss, particularly in older individuals vulnerable to sarcopenia.

A plain-English summary is on its way. Until then, this is the start of the authors' own summary.

Tested inAnimals
Who it was tested in
Not stated
Kind of research
Early results, not yet checked by other scientists

The science

Original title
Aging exacerbates muscle loss induced by semaglutide treatment in female mice
Authors
Rout, S., Karasawa, T., Moore, E. R. et al.
Journal
bioRxiv (preprint, not yet peer reviewed)
Published
Nov 13, 2026
Study type
Preprint

Abstract

Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide, have transformed the pharmacological treatment of obesity. While highly efficacious in promoting weight loss, these drugs also induce substantial reductions in lean mass, raising concerns for skeletal muscle loss, particularly in older individuals vulnerable to sarcopenia. Nevertheless, there are currently no published human studies that investigated the effects of GLP-1RAs on skeletal muscle mass using gold standard methods. Meanwhile, studies in young mice demonstrate that skeletal muscle loss induced by GLP-1RAs might not be a major concern. The purpose of the current study was to investigate the effects of semaglutide on skeletal muscle mass and strength in aged mice. Methods Eighteen-month-old male and female C57BL/6J mice were fed a high-fat diet (HFD) for 12 weeks to induce obesity. At 21 months of age, mice received daily subcutaneous injections of vehicle or semaglutide (3 or 30 nmol/kg) for 3 weeks. Body composition was assessed weekly by nuclear magnetic resonance (NMR) spectroscopy. After 3 wks, mice were terminated to assess masses of individual organs including skeletal muscle. Skeletal muscle force-generating capacity was assessed by ex vivo electrical stimulation-induced contraction. Myofiber cross-sectional area and fiber-type composition were also assessed. Results Semaglutide induced dose-dependent weight loss in both sexes, with reductions of 11.3% and 20.2% in males and 21.1% and 26.1% in females receiving 3 or 30 nmol/kg dose, respectively. There was a substantial sex-difference in the loss of lean mass, with relatively minor reductions in males (2.3% and 6.6%) and greater loss in females (8.6% and 8.3%). Skeletal muscle mass was largely preserved in males but females exhibited greater muscle mass loss, including 14.2% reduction in quadriceps mass at 30 nmol/kg of semaglutide treatment. In contrast, skeletal muscle force-generating capacity was not compromised in semaglutide-treated females, while males exhibited 19.2% reduction in force generating capacity of the extensor digitorum longus (EDL) muscles at the 30 nmol/kg dose. Conclusion Unlike young mice, semaglutide treatment may induce meaningful loss in skeletal muscle mass in aged female mice and muscle strength in aged male mice. These findings highlight the importance of considering age as a potential factor that may negatively influence muscle mass and function in humans treated with GLP-1RAs. Clinical studies examining the influence of pharmacological weight loss on skeletal muscle mass and strength should consider both age and sex as a potentially important determinant of these outcomes.

Read it on bioRxiv ↗

Rout, S., Karasawa, T., Moore, E. R. et al. Aging exacerbates muscle loss induced by semaglutide treatment in female mice. bioRxiv. 2026. doi:10.64898/2026.11.11.766063. https://doi.org/10.64898/2026.11.11.766063

Related research

AnimalsStudy · bioRxiv : the preprint server for biology · Nov 20, 2026

Aging exacerbates muscle loss induced by semaglutide treatment in female mice.

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide, have transformed the pharmacological treatment of obesity.

Summary of earlier studiesReview · Journal of cosmetic dermatology · Nov 18, 2026

Review compares six collagen fillers for face loss linked to weight-loss drugs

This review looked at 43 studies of six types of collagen-building fillers and how each may signal cells. It does not show which filler works best, and no study tested people on these drugs.

Summary of earlier studiesReview · The lancet. HIV · Nov 8, 2026

Weight management in people with HIV.

Excess weight gain in people with HIV is now recognised as a common risk associated with the use of guideline-recommended antiretroviral therapy, such that nearly 50% of people with HIV are living with comorbid obesity.

PeopleClinical trial · Journal of drugs in dermatology : JDD · Sep 4, 2026

A skin serum showed visible improvements in older women over 12 weeks

Women aged 45 and older used a facial serum twice a day for 12 weeks. Experts and participants saw changes in fine lines, wrinkles, and skin hydration. This study had no comparison group, so it cannot show the serum caused the changes.

Study · Journal of the American Geriatrics Society · Oct 29, 2026

Doctors' group offers a guide for using weight-loss drugs like GLP-1 in older adults

Experts wrote a guide on weighing benefits and risks, such as muscle loss, when older adults take these drugs. It is advice built from example patient cases, not a new study testing the drugs.

AnimalsStudy · GeroScience · Oct 23, 2026

Lessons from dog lifespan therapeutics for their human companions.

The growing evidence that existing cardio-renal-metabolic therapies, such as GLP-1 receptor agonists and SGLT2 inhibitors, confer all-cause mortality benefits has positioned them as the first wave of potential…

See all research on GLP-1 drugs →

Report a problem